wakey wakey mr market, page-97

Just some points to note re the phase II / III trial:

The CANVAS Trial now has @ 80 of 95 sites now recruiting or reading to recruit
- This is a significant number of the total sites being utilised for this trial.

Estimated enrollment is 1000 (clinicaltrials.gov)
- Statistically significant data can be reached for analysis upon relapse of
400 patients.

Estimated study completion - December 2015
- This is only 17 months away

Median survival of patients with recurrent ovarian cancer ranges from 12-24 months, demonstrating the chronic natural history of the disease
http://theoncologist.alphamedpress.org/content/7/suppl_5/20.full
- This is a poor prognosis which desperately needs a treatment other than
chemo or radiation therapy to expect life expectancy and improve quality
of life.

It seems that Prima may be expecting significant data for analysis as shown above, I hope that is the case anyway. The sooner this treatment (as long as it is shown to be of sufficient benefit as per the guidelines) is commercialised, the better.